8 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Exploiting MELanoma disease comPLEXity to address European research training needs in translational cancer systems biology and cancer systems medicine (MEL-PLEX)
Date du début: 1 déc. 2014, Date de fin: 30 nov. 2018,
Novel treatment options and associated personalised, patient-tailored therapies need to be explored and developed for highly heterogeneous and chemotherapy resistant cancers, such as malignant melanoma. This can only be achieved by industry-academia collaborations in newly emerging, innovative research disciplines such as translational cancer systems biology and systems medicine. These disciplines ...
Voir le projet
11
Participants partenaires
TERMINÉ
OncoMasTR - Novel Prognostic Assay for Early Stage Breast Cancer (OncoMasTR)
Date du début: 1 févr. 2016, Date de fin: 31 janv. 2018,
OncoMark Ltd are developing a novel, game-changing breast cancer prognostic assay, called OncoMasTR, which has the potential to transform clinical practice and patient care. OncoMasTR will help clinicians to decide which patients should receive chemotherapy for early stage breast cancer, which is a pressing clinical and economic issue worldwide. OncoMasTR is more cost-effective than competitor ass ...
Voir le projet
1
Participant partenaire
TERMINÉ
SYSTEMS-BASED VIEW OF MELANOMA PROGRESSION: TOWARDS NOVEL DIAGNOSTIC (AND THERAPEUTIC) APPLICATIONS (SYS-MEL)
Date du début: 1 nov. 2013, Date de fin: 31 oct. 2017,
Worldwide figures show that there were 160,000 incidences of melanoma in 2002, whilst 39,000 died from the disease. These upward trends are worrying, as malignant melanoma is one of the most difficult cancers to treat, due to its ability to spread quickly and its resistance to standard chemotherapeutic agents. In order to counteract this trend, targeted therapies that inhibit melanoma metastasis a ...
Voir le projet
7
Participants partenaires
TERMINÉ
Rational Therapy for Breast Cancer: Individualized Treatment for Difficult-to-Treat Breast Cancer Subtypes (RATHER)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,
"Cancer genotyping has identified a number of correlations between mutations in specific genes and responses to targeted anti-cancer drugs, with many mutations occurring in kinases or downstream signaling components. While there are several ongoing large-scale genome re-sequencing studies for the major cancer types, there is no systematic effort to investigate kinase mutations in distinct biologic ...
Voir le projet
8
Participants partenaires
TERMINÉ
Predictive Genomic Biomarkers Methods for Combination Bevacizumab (Avastin) Therapy in Metastatic Colorectal Cancer (ANGIOPREDICT)
Date du début: 1 févr. 2012, Date de fin: 31 janv. 2016,
In recent years the treatment paradigm for metastatic colorectal cancer (mCRC) has evolved in complexity to include newly developed targeted therapeutics. In 2004 bevacizumab (bvz) [Avastin] became the first anti-angiogenic drug to be licensed in malignant disease, based on the results of a randomised trial in advanced metastatic colorectal cancer. Nevertheless, over the past six year period emerg ...
Voir le projet
12
Participants partenaires
TERMINÉ
Fast-Tracking Pathology via Automated Image Analysis and High-Performance Computing: Application to Prostate Cancer Diagnostics (FAST-PATH)
Date du début: 1 nov. 2011, Date de fin: 31 oct. 2015,
Histopathology has traditionally been a low-throughput, labour-intensive technique. Conventional manual annotation of tissue slides requires a pathologist to examine the tissue and cellular components to grade the level of disease progression. However, digital pathology and automated digital image analysis solutions can provide a more rapid solution. In recent years, there has been a rapid uptake ...
Voir le projet
6
Participants partenaires
TERMINÉ
Apoptosis Modelling for Treatment Decisions in Colorectal Cancer (APO-DECIDE)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2014,
"With the arrival of new colorectal cancer (CRC) therapeutics targeting specific cell signalling pathways, such as anti-EGFR therapy, personalised cancer treatment is at the door step of clinical practise. This progress in drug development contrasts strikingly with current clinical practice, where decision making depends largely on clinical factors such as tumour staging and age of patient, with t ...
Voir le projet
7
Participants partenaires
TERMINÉ
Histopathologic and Mechanistic Assessment of Angiogenesis Inhibitor Related Toxicities: A Cross-Sectoral, Multi-disciplinary Approach (ANGIOTOX)
Date du début: 1 juil. 2010, Date de fin: 30 juin 2014,
Inhibition of angiogenesis, the formation of new blood vessels from pre-existing vasculature, is a well established therapeutic strategy against cancer. Inhibitors of angiogenesis have been developed to block tumour growth and metastasis, and a number of these inhibitors are now clinically approved. However, contrary to initial expectations, angiogenesis inhibitors can cause a range of toxicities ...
Voir le projet